ABL Bio Inc. (KOSDAQ:298380)
South Korea
· Delayed Price · Currency is KRW 190,600
-10,400 (-5.17%)
At close: Dec 5, 2025
ABL Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 88,437 | 33,403 | 65,547 | 67,301 | 5,332 |
| Other Revenue | -0 | -0 | 0 | -0 | 0 |
| Revenue | 88,437 | 33,403 | 65,547 | 67,301 | 5,332 |
| Revenue Growth (YoY) | 173.62% | -49.04% | -2.61% | 1162.19% | - |
| Cost of Revenue | 58.8 | 61.26 | 46.25 | 83.76 | 47.98 |
| Gross Profit | 88,378 | 33,342 | 65,501 | 67,217 | 5,284 |
| Selling, General & Admin | 19,521 | 16,231 | 13,493 | 15,569 | 13,962 |
| Research & Development | 95,607 | 74,079 | 52,035 | 48,416 | 41,034 |
| Operating Expenses | 118,218 | 92,719 | 68,118 | 66,309 | 56,472 |
| Operating Income | -29,840 | -59,377 | -2,617 | 908 | -51,188 |
| Interest Expense | -608.33 | -36.04 | -2,151 | -1,326 | -41.98 |
| Interest & Investment Income | 3,042 | 1,877 | 1,294 | 233.75 | 99.72 |
| Currency Exchange Gain (Loss) | -883.29 | 1,373 | 734.04 | 1,761 | 864.43 |
| Other Non Operating Income (Expenses) | 207 | 249.56 | -1,037 | 2,176 | 47.62 |
| EBT Excluding Unusual Items | -28,083 | -55,914 | -3,776 | 3,753 | -50,218 |
| Gain (Loss) on Sale of Investments | -583.53 | 391.27 | 1,132 | -592.13 | 6,666 |
| Gain (Loss) on Sale of Assets | -7.03 | -7.03 | -2.64 | 48 | -5.83 |
| Pretax Income | -28,673 | -55,529 | -2,647 | 3,209 | -43,558 |
| Net Income | -28,645 | -55,529 | -2,647 | 3,209 | -43,558 |
| Net Income to Common | -28,645 | -55,529 | -2,647 | 3,209 | -43,558 |
| Shares Outstanding (Basic) | 50 | 48 | 48 | 48 | 47 |
| Shares Outstanding (Diluted) | 50 | 48 | 48 | 48 | 47 |
| Shares Change (YoY) | 3.78% | 0.37% | 0.58% | 1.27% | - |
| EPS (Basic) | -575.91 | -1156.34 | -55.32 | 67.46 | -927.36 |
| EPS (Diluted) | -575.91 | -1156.34 | -55.32 | 67.46 | -927.36 |
| Free Cash Flow | -54,029 | -78,426 | -34,102 | 70,076 | -41,850 |
| Free Cash Flow Per Share | -1086.27 | -1633.14 | -712.77 | 1473.23 | -890.99 |
| Gross Margin | 99.93% | 99.82% | 99.93% | 99.88% | 99.10% |
| Operating Margin | -33.74% | -177.76% | -3.99% | 1.35% | -959.99% |
| Profit Margin | -32.39% | -166.24% | -4.04% | 4.77% | -816.91% |
| Free Cash Flow Margin | -61.09% | -234.79% | -52.03% | 104.12% | -784.87% |
| EBITDA | -26,750 | -56,967 | -27.32 | 3,233 | -49,029 |
| EBITDA Margin | -30.25% | -170.55% | -0.04% | 4.80% | - |
| D&A For EBITDA | 3,091 | 2,410 | 2,590 | 2,325 | 2,158 |
| EBIT | -29,840 | -59,377 | -2,617 | 908 | -51,188 |
| EBIT Margin | -33.74% | -177.76% | -3.99% | 1.35% | - |
Source: S&P Capital IQ. Standard template. Financial Sources.